Core Viewpoint - The animal health sector experienced a decline of 0.59% on December 29, with the driving force leading the drop, while the Shanghai Composite Index rose by 0.04% to close at 3965.28 [1] Group 1: Market Performance - The animal health sector's individual stock performance showed mixed results, with notable declines in several stocks, including: - Driving Force (Code: 920275) down by 1.78% to 8.84 - ST Green Health (Code: 002868) down by 1.50% to 33.58 - Yongshun Biological (Code: 920729) down by 1.47% to 8.70 [2] - The overall trading volume in the animal health sector indicated a net outflow of 127 million yuan from main funds, while retail investors saw a net inflow of 61.75 million yuan [2][3] Group 2: Individual Stock Analysis - Key individual stock performances included: - Huisheng Biological (Code: 300871) closed at 20.70 with a slight increase of 0.44% and a trading volume of 50,100 shares [1] - Driving Force (Code: 920275) had a trading volume of 9,094.74 shares and a net outflow of 408,300 yuan from main funds [3] - ST Green Health (Code: 002868) saw a significant net outflow of 534,110 yuan from main funds, indicating weak investor sentiment [3] - The stock with the highest decline was Xianfeng Holdings (Code: 002141), which fell by 0.81% to 3.68, with a net outflow of 722,640 yuan from main funds [3]

消费行业 2025 年总结与 2026 年展望 20251228 摘要 2025 年创新药 BD 爆发，前三季度出海金额达 920 亿美元，创销板块 表现突出，港股通创销板块涨幅高达 73%。预计 2026 年中国创新药将 通过 BD 方式更深入参与全球市场，推动生态体系变化。 2025 年 A 股社服零售板块表现偏后，但免税行业在 9 月已现复苏迹象。 展望 2026 年，服务消费负贝塔效应将减弱，政策倾斜预期增强，免税 和酒店估值修复，业绩兑现窗口或将到来。 2025 年第四季度家电行业处于消化期，国家补贴边际效应降低，出口 负增长。2026 年建议关注红利、全球化、AI 端侧应用和零部件跨界四 大领域，白电龙头红利价值较高，全球化关注关税影响。 2025 年轻纺行业内需承压，外贸受关税和汇率扰动，金饰表现亮眼。 2026 年仍需自下而上挖掘高景气成长股，优选具备竞争力的外贸品种， 关注金饰、服饰、制造业和个护等细分赛道。 2025 年农业牧渔行业机会偏小波段且结构性明显，生猪养殖板块占比 最大。预计 2026 年生猪产能去化将持续推动猪价上涨，建议重仓生猪 养殖主线，关注优质资产和弹性标的。 Q&A 2 ...

Investment Rating - The report maintains an "Overweight" rating for the agriculture, forestry, animal husbandry, and fishery industry [1][42] Core Views - The SW agriculture, forestry, animal husbandry, and fishery industry slightly underperformed the CSI 300 index, with an increase of 1.55% from December 12 to December 25, 2025, lagging behind the index by approximately 0.43 percentage points [11][14] - All sub-sectors recorded positive returns during the same period, with notable increases in agricultural product processing (3.04%), animal health (2.95%), planting (2.28%), fishery (1.56%), breeding (0.81%), and feed (0.29%) [14][15] - The overall price-to-book (PB) ratio for the industry is approximately 2.79 times, indicating a slight recovery in valuation, which remains at a historical low level, around the 62.7 percentile since 2006 [18][24] Industry Important Data - **Pig Farming**: The average price of external three-way cross pigs increased from 11.45 CNY/kg to 11.59 CNY/kg during the reporting period. The cost of corn and soybean meal has slightly decreased, with corn priced at 2338.04 CNY/ton and soybean meal at 3102 CNY/ton as of December 25, 2025 [22][24] - **Profitability**: As of December 26, 2025, the profit for self-bred pigs was -130.11 CNY/head, and for purchased piglets, it was -162.8 CNY/head, showing a reduction in losses compared to the previous two weeks [27] - **Poultry Farming**: The average price of broiler chicks was 3.59 CNY/chick, showing a slight increase, while the average price for white feather broilers was 7.82 CNY/kg, with profitability improving to 0.89 CNY/chick [29][33] Industry Insights - The report emphasizes the potential for a rebound in pig prices as the seasonal consumption peak approaches, with a focus on the high inventory of breeding sows and the opportunities for leading pig farming companies [42][43] - In poultry farming, the report highlights the recovery in white feather broiler prices and the improvement in profitability, suggesting a positive outlook for leading poultry companies [42][43] - The report also notes growth potential in the domestic pet market and the expected increase in export volumes, recommending attention to promising domestic leaders in this sector [42][43]

证券之星消息，12月26日动物保健板块较上一交易日下跌1.01%，生物股份领跌。当日上证指数报收于 3963.68，上涨0.1%。深证成指报收于13603.89，上涨0.54%。动物保健板块个股涨跌见下表： | 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 600195 | 中牧股份 | 8.00 | 0.13% | 9.70万 | 7760.85万 | | 920729 | 永顺生物 | 8.83 | 0.11% | 4509.29 | 398.88万 | | 002141 | 后丰控股 | 3.71 | -0.27% | 15.43万 | 5712.69万 | | 300119 | 瑞普生物 | 19.37 | -0.31% | 2.94万 | 5701.35万 | | 688526 | 科前生物 | 15.62 | -0.38% | 1.90万 | 2965.26万 | | 688098 | 申联生物 | 8.91 | -0.67% | 2.81万 | 2511.39万 | | 603566 ...

当宠物经济成为消费市场的"常青树"，赛道龙头终于向资本市场发起冲击。 近日，中国第二大宠物医疗服务提供商瑞派宠物医院管理股份有限公司（下称"瑞派宠物"）正式向港交所递交招股书，拟冲刺"中国宠物医疗第一股"。 文｜财华社 他在中国农业大学获得预防兽医学博士学位，享受国务院政府特殊津贴，亦是俄罗斯工程院外籍院士。同时，他担任科技部兽药产业技术创新战略联盟理事 长、中国畜牧兽医学会理事、中国兽药协会副会长等多项社会职务，曾获"国家科学技术进步二等奖""农业技术推广贡献奖"等重量级奖项。 学术与产业的双重深耕，让李守军敏锐捕捉到宠物经济的崛起机遇。早在1998年，他便创立瑞普生物，深耕动物保健领域，并于2010年带领公司登陆创业 板，成为行业标杆。 随着养宠需求从"基础饲养"转向"健康管理"，李守军于2012年跨界创立瑞派宠物，形成"动物保健+宠物医疗"双赛道布局，凭借对行业痛点的深刻洞察，构 建出差异化的连锁医疗体系。 在李守军的带领下，瑞派宠物迅速崛起为宠物医疗领域的实力玩家。 根据公司官网及招股书，公司已成为中国首家实现全国连锁化运营的宠物医疗服务提供商，截至2025年6月30日，旗下有医院548家（其中22家 ...

证券代码：300119 证券简称：瑞普生物 公告编号：2025-100 瑞普生物股份有限公司 关于取得新兽药注册证书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 根据《兽药管理条例》和《兽药注册办法》的规定，瑞普生物股份有限公司 （以下简称"公司""瑞普生物"）及下属分子公司天津瑞普生物技术股份有限 公司空港经济区分公司、瑞普（保定）生物药业有限公司 2 款新兽药产品近日获 农业农村部批准，详情如下： 原体流行菌株，能够显著减少免疫猪群肺炎病变损伤；副猪嗜血杆菌抗原覆盖主 要流行血清型 4 型、5 型菌株，可有效降低或阻断相应菌株感染。该产品采用无 血清全悬浮细胞培养、细菌高密度发酵和高效的浓缩纯化等先进技术，实现制苗 抗原的精纯制备；开发相对效力标准和菌体蛋白浓度制苗标准，实现工艺稳定、 均一可控；搭配兼顾多种抗原组合安全性和免疫效果的水性佐剂，显著降低副反 应发生率。该疫苗免疫后 4 周可产生免疫力，免疫持续期可达 5 个月，实现"一 针三防"，大幅简化临床免疫程序，助力养殖场提升免疫效率、节省人力成本、 减少猪群临床免疫应激。 该产品的成功获批 ...

Group 1 - The animal vaccine sector experienced a decline of 0.47%, ranking among the top losers in concept sectors, with notable declines from companies like BioShares, Luo Niu Shan, and Tian Kang Bio [1] - Among the stocks in the animal vaccine sector, 10 stocks saw price increases, with Hengtong Co., Hai Zheng Pharmaceutical, and Hai Li Bio leading the gains at 3.67%, 0.69%, and 0.48% respectively [1] - The main capital outflow from the animal vaccine sector today was 87 million yuan, with 14 stocks experiencing net outflows, led by Luo Niu Shan with a net outflow of 95.06 million yuan [2] Group 2 - The top net inflow stocks in the animal vaccine sector included BioShares, Da Bei Nong, and Zhong Mu Co., with net inflows of 46.84 million yuan, 6.50 million yuan, and 3.83 million yuan respectively [2][3] - The capital outflow leaderboard for the animal vaccine sector included Luo Niu Shan, Hengtong Co., and Rui Pu Bio, with respective outflows of 95.06 million yuan, 11.49 million yuan, and 7.66 million yuan [2][3] - The trading activity showed that Luo Niu Shan had a turnover rate of 16.52%, while other companies like Hengtong Co. and Tian Kang Bio had turnover rates of 3.51% and 1.98% respectively [2][3]

Group 1: Pig Farming Industry - The supply-demand structure of the pig farming industry is improving, but short-term oversupply will continue to pressure pig prices in the first half of 2026, leading to ongoing industry losses [2][3] - Cost is a core factor for pig companies to achieve excess returns and long-term growth, especially significant during the down cycle [2] - The industry is experiencing a shift towards larger-scale farming, which is reshaping the market dynamics and reducing the volatility of pig prices [2][3] Group 2: Feed and Animal Health - The animal health sector is seeing a weakening of its cyclical attributes, with research and innovation becoming the core competitive advantage for long-term growth [4] - The feed industry is expected to benefit from high livestock inventory supporting demand, while the aquatic feed sector is expected to operate steadily under rational farming behavior [5] - Domestic market competition is fierce, with leading feed companies expected to enhance their competitiveness through cost control and refined management [5] Group 3: Pet Food Market - The pet food market is experiencing a reshaping of global supply-demand dynamics due to tariff disturbances, but domestic consumption remains robust [6] - There is a clear trend of domestic brands rising in the pet food sector, with companies adapting to health and refinement trends in consumer preferences [6] - Recommended stocks in the pet food industry include Zhongchong Co., Ltd. (002891.SZ) and Petty Co., Ltd. (300673.SZ) [6]

Core Viewpoint - The capital is not abandoning the pet industry but is becoming more selective, focusing on key segments within the industry that show potential for growth and innovation [1]. Group 1: Investment Trends - In 2023, there were 33 public financing events in the domestic pet industry, with 5 of them being billion-level financings, indicating strong interest in the sector [3]. - The pet medical and pharmaceutical sectors are the most favored, with over 13 financing events, highlighting a preference for companies with core technologies, particularly in vaccine and new drug development [3]. - The pet food sector shows uneven investment, with established brands receiving more attention than new entrants, reflecting a shift from "traffic competition" to "supply chain competition" [3]. Group 2: Industry Integration - The pet industry is experiencing accelerated consolidation, with 7 major mergers and acquisitions and the establishment of 5 industry funds, totaling over 2 billion [5]. - Companies like Yiyi Co. and New Hope Group are actively acquiring brands to enhance their product lines, while firms like New Ruipeng and Ruipu Biological are launching funds covering various segments [5]. Group 3: Changing Investment Focus - Capital is increasingly focused on companies with standardized services and resource barriers, moving from fragmented services to scaled and digital operations [4]. - Investment institutions are now prioritizing companies that possess core technologies, stable production capacity, and the ability to offer differentiated services, marking a departure from previous models that emphasized rapid scaling and quick profits [6].

Core Viewpoint - Ruipai Pet Hospital has submitted its listing application to the Hong Kong Stock Exchange, aiming to expand its national chain of pet medical services and enhance its operational capabilities [1][4]. Group 1: Company Overview - Ruipai Pet Hospital is a national chain of pet medical institutions, focusing on diagnostic services, which include basic and specialized medical care [2][4]. - The company was established in 2012 and is recognized as the first pet medical service provider in China to achieve nationwide chain operations, with a goal of creating a standardized and replicable pet health management service system [4]. - As of June 30, 2025, Ruipai Pet Hospital is the second-largest pet medical service provider in China, operating in approximately 70 cities across 28 provinces [4]. Group 2: Financial Performance - The company's revenue is primarily derived from diagnostic services, with supplementary income from pet product sales, grooming services, and other offerings. The revenue figures for 2022, 2023, 2024, and the first half of 2025 are 1.455 billion, 1.585 billion, 1.758 billion, and 943 million yuan, respectively [5]. - The net profit figures for the same periods are -62.237 million, -251 million, -58.713 million, and 15.54 million yuan, indicating significant fluctuations in profitability [2][5]. - The company plans to use the net proceeds from the listing to expand its hospital network, enhance health management services, develop IT infrastructure, and for brand marketing and general corporate purposes [5]. Group 3: Supplier Relationships - Ruipai Pet Hospital's primary customers are individual pet owners, with approximately 1.216 million, 1.360 million, 1.430 million, and 865,400 pet owners served in 2022, 2023, 2024, and the first half of 2025, respectively [6]. - The largest supplier, Ruipu Bio, accounted for 22.5% of the company's total procurement as of the first half of 2025, with total procurement from the top five suppliers representing 32.9% of the total [3][6].